Education
About Us
Working with TipRanks
Follow Us
Sana Biotechnology (SANA)
NASDAQ:SANA
SANA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.26 - $10.50
Previous CloseN/A
Volume118.31M
Average Volume (3M)4.29M
Market Cap
$396.04M
Enterprise Value$872.56M
Total Cash (Recent Filing)$176.76M
Total Debt (Recent Filing)$108.25M
Price to Earnings (P/E)―
Beta1.32
Next Earnings
May 13, 2025EPS Estimate
-0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.17
Shares Outstanding225,024,900
10 Day Avg. Volume5,763,731
30 Day Avg. Volume4,289,818
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.80
P/FCF Ratio0.00
Enterprise Value/Market Cap2.20
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-3.45
Forecast
1Y Price Target
$7.50Price Target Upside326.14% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
Bulls Say, Bears Say
Bulls Say
Executive LeadershipThe company appointed new executives to the C-suite, bringing experience from major companies like UCB, Novartis, Genentech, Roche, and Fibrogen.
Technology ValidationSana Biotechnology continues to provide positive data updates for UP421 in Type 1 Diabetes, further validating its HIP-editing platform.
Bears Say
Clinical Data ConcernsSome investors note that the C-peptide levels were significantly lower than normal levels and therefore not enough for the patients to achieve insulin independence.
Financial PerformanceSana reported no revenues for 4Q24, with R&D and SG&A expenses higher than estimated.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
SANA FAQ
What was Sana Biotechnology’s price range in the past 12 months?
Sana Biotechnology lowest stock price was $1.26 and its highest was $10.50 in the past 12 months.
What is Sana Biotechnology’s market cap?
Sana Biotechnology’s market cap is $396.04M.
When is Sana Biotechnology’s upcoming earnings report date?
Sana Biotechnology’s upcoming earnings report date is May 13, 2025 which is in 29 days.
How were Sana Biotechnology’s earnings last quarter?
Sana Biotechnology released its earnings results on Mar 17, 2025. The company reported -$0.21 earnings per share for the quarter, beating the consensus estimate of -$0.246 by $0.036.
Is Sana Biotechnology overvalued?
According to Wall Street analysts Sana Biotechnology’s price is currently Undervalued.
Does Sana Biotechnology pay dividends?
Sana Biotechnology does not currently pay dividends.
What is Sana Biotechnology’s EPS estimate?
Sana Biotechnology’s EPS estimate is -0.23.
How many shares outstanding does Sana Biotechnology have?
Sana Biotechnology has 225,024,900 shares outstanding.
What happened to Sana Biotechnology’s price movement after its last earnings report?
Sana Biotechnology reported an EPS of -$0.21 in its last earnings report, beating expectations of -$0.246. Following the earnings report the stock price went down -17.69%.
Which hedge fund is a major shareholder of Sana Biotechnology?
Currently, no hedge funds are holding shares in SANA
---
Sana Biotechnology Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.50 (326.14% Upside)
$7.50 (326.14% Upside)
Blogger Sentiment
Bullish
SANA Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 115.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 0.5%
Last 30 Days ▼ 2.2%
Last 30 Days ▼ 2.2%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-81.19%
12-Months-Change
Fundamentals
Return on Equity
-99.17%
Trailing 12-Months
Asset Growth
-11.37%
Trailing 12-Months
Company Description
Sana Biotechnology
Sana Biotechnology (SANA) is a leading biotechnology company focused on developing and delivering engineered cells as medicines for patients. Operating within the biotechnology and pharmaceutical sectors, Sana specializes in advancing in vivo and ex vivo cell engineering platforms with the goal of treating a range of diseases including cancer, genetic disorders, and other serious illnesses. The company's core technologies aim to repair or control genes and replace damaged cells with healthy ones, offering innovative solutions that address unmet medical needs.
---
SANA Stock 12 Month Forecast
Average Price Target
$7.50
▲(326.14% Upside)
Technical Analysis
Dianthus Therapeutics
―
Autolus Therapeutics
―
Xeris Pharmaceuticals
―
Tectonic Therapeutic
―
Best Analysts Covering SANA
1 Year
1 Year Success Rate
2/9 ratings generated profit
1 Year Average Return
-30.76%
reiterated a buy rating 3 months ago
Copying Samantha Semenkow's trades and holding each position for 1 Year would result in 22.22% of your transactions generating a profit, with an average return of -30.76% per trade.
---